BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 33718514)

  • 1. Effective, safe, and sustained correction of murine XLA using a UCOE-BTK promoter-based lentiviral vector.
    Seymour BJ; Singh S; Certo HM; Sommer K; Sather BD; Khim S; Clough C; Hale M; Pangallo J; Ryu BY; Khan IF; Adair JE; Rawlings DJ
    Mol Ther Methods Clin Dev; 2021 Mar; 20():635-651. PubMed ID: 33718514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia.
    Kerns HM; Ryu BY; Stirling BV; Sather BD; Astrakhan A; Humblet-Baron S; Liggitt D; Rawlings DJ
    Blood; 2010 Mar; 115(11):2146-55. PubMed ID: 20093406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained correction of B-cell development and function in a murine model of X-linked agammaglobulinemia (XLA) using retroviral-mediated gene transfer.
    Yu PW; Tabuchi RS; Kato RM; Astrakhan A; Humblet-Baron S; Kipp K; Chae K; Ellmeier W; Witte ON; Rawlings DJ
    Blood; 2004 Sep; 104(5):1281-90. PubMed ID: 15142874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction of B-cell development in Btk-deficient mice using lentiviral vectors with codon-optimized human BTK.
    Ng YY; Baert MR; Pike-Overzet K; Rodijk M; Brugman MH; Schambach A; Baum C; Hendriks RW; van Dongen JJ; Staal FJ
    Leukemia; 2010 Sep; 24(9):1617-30. PubMed ID: 20574453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing Integration and Expression of Transgenic Bruton's Tyrosine Kinase for CRISPR-Cas9-Mediated Gene Editing of X-Linked Agammaglobulinemia.
    Gray DH; Villegas I; Long J; Santos J; Keir A; Abele A; Kuo CY; Kohn DB
    CRISPR J; 2021 Apr; 4(2):191-206. PubMed ID: 33876953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages.
    de Weers M; Verschuren MC; Kraakman ME; Mensink RG; Schuurman RK; van Dongen JJ; Hendriks RW
    Eur J Immunol; 1993 Dec; 23(12):3109-14. PubMed ID: 8258324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid tyrosine phosphorylation and activation of Bruton's tyrosine/Tec kinases in platelets induced by collagen binding or CD32 cross-linking.
    Oda A; Ikeda Y; Ochs HD; Druker BJ; Ozaki K; Handa M; Ariga T; Sakiyama Y; Witte ON; Wahl MI
    Blood; 2000 Mar; 95(5):1663-70. PubMed ID: 10688822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of B-lineage predominant lentiviral vectors for use in genetic therapies for B cell disorders.
    Sather BD; Ryu BY; Stirling BV; Garibov M; Kerns HM; Humblet-Baron S; Astrakhan A; Rawlings DJ
    Mol Ther; 2011 Mar; 19(3):515-25. PubMed ID: 21139568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation analysis of the Bruton's tyrosine kinase gene in X-linked agammaglobulinemia: identification of a mutation which affects the same codon as is altered in immunodeficient xid mice.
    de Weers M; Mensink RG; Kraakman ME; Schuurman RK; Hendriks RW
    Hum Mol Genet; 1994 Jan; 3(1):161-6. PubMed ID: 8162018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bruton's tyrosine kinase is not essential for LPS-induced activation of human monocytes.
    Pérez de Diego R; López-Granados E; Pozo M; Rodríguez C; Sabina P; Ferreira A; Fontan G; García-Rodríguez MC; Alemany S
    J Allergy Clin Immunol; 2006 Jun; 117(6):1462-9. PubMed ID: 16751014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. X-chromosome inactivation and mutation pattern in the Bruton's tyrosine kinase gene in patients with X-linked agammaglobulinemia. Italian XLA Collaborative Group.
    Moschese V; Orlandi P; Plebani A; Arvanitidis K; Fiorini M; Speletas M; Mella P; Ritis K; Sideras P; Finocchi A; Livadiotti S; Rossi P
    Mol Med; 2000 Feb; 6(2):104-13. PubMed ID: 10859027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling.
    Lindvall JM; Blomberg KE; Väliaho J; Vargas L; Heinonen JE; Berglöf A; Mohamed AJ; Nore BF; Vihinen M; Smith CI
    Immunol Rev; 2005 Feb; 203():200-15. PubMed ID: 15661031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton's tyrosine kinase expression and activity in X-linked agammaglobulinaemia (XLA): the use of protein analysis as a diagnostic indicator of XLA.
    Gaspar HB; Lester T; Levinsky RJ; Kinnon C
    Clin Exp Immunol; 1998 Feb; 111(2):334-8. PubMed ID: 9486400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular and structural characterization of five novel mutations in the Bruton's tyrosine kinase gene from patients with X-linked agammaglobulinemia.
    Saha BK; Curtis SK; Vogler LB; Vihinen M
    Mol Med; 1997 Jul; 3(7):477-85. PubMed ID: 9260159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed diagnosis in X-linked agammaglobulinemia and its relationship to the occurrence of mutations in BTK non-kinase domains.
    Carrillo-Tapia E; García-García E; Herrera-González NE; Yamazaki-Nakashimada MA; Staines-Boone AT; Segura-Mendez NH; Scheffler-Mendoza SC; O Farrill-Romanillos P; Gonzalez-Serrano ME; Rodriguez-Alba JC; Santos-Argumedo L; Berron-Ruiz L; Sanchez-Flores A; López-Herrera G
    Expert Rev Clin Immunol; 2018 Jan; 14(1):83-93. PubMed ID: 29202590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation screening of the BTK gene in 56 families with X-linked agammaglobulinemia (XLA): 47 unique mutations without correlation to clinical course.
    Holinski-Feder E; Weiss M; Brandau O; Jedele KB; Nore B; Bäckesjö CM; Vihinen M; Hubbard SR; Belohradsky BH; Smith CI; Meindl A
    Pediatrics; 1998 Feb; 101(2):276-84. PubMed ID: 9445504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the Bruton's tyrosine kinase gene promoter reveals critical PU.1 and SP1 sites.
    Himmelmann A; Thevenin C; Harrison K; Kehrl JH
    Blood; 1996 Feb; 87(3):1036-44. PubMed ID: 8562928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletion within the Src homology domain 3 of Bruton's tyrosine kinase resulting in X-linked agammaglobulinemia (XLA).
    Zhu Q; Zhang M; Rawlings DJ; Vihinen M; Hagemann T; Saffran DC; Kwan SP; Nilsson L; Smith CI; Witte ON; Chen SH; Ochs HD
    J Exp Med; 1994 Aug; 180(2):461-70. PubMed ID: 7519238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics and prenatal diagnosis for 22 families in Henan Province of China with X-linked agammaglobulinemia (XLA) related to Bruton's tyrosine kinase (BTK) gene mutations.
    Gao S; Hu S; Duan H; Wang L; Kong X
    BMC Med Genet; 2020 Jun; 21(1):131. PubMed ID: 32552675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An exon-skipping mutation in the btk gene of a patient with X-linked agammaglobulinemia and isolated growth hormone deficiency.
    Duriez B; Duquesnoy P; Dastot F; Bougnères P; Amselem S; Goossens M
    FEBS Lett; 1994 Jun; 346(2-3):165-70. PubMed ID: 8013627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.